Enabling Next-generation Therapeutics
Many promising anti-cancer drugs antibody-drug conjugates (ADCs) have limited impact because they are trapped in cellular endosomes after entering cancer cells.
Defence Therapeutics’ proprietary Accum platform overcomes this barrier by enabling efficient endosomal escape, ensuring these life-saving drugs are released into the cell where they can unleash their full therapeutic effect.
Our technology transforms the intracellular delivery landscape for cancer therapeutics, opening new possibilities for cancer treatment.
The Issue
Antibody-drug conjugates (ADCs) are a growing class of cancer therapeutics that often fail to reach optimal efficacy because after entering cancer cells, they become trapped inside compartments called endosomes. Endosomes act as barriers within cancer-resistant cells, sequestering ADCs and preventing their toxic payload from being released throughout the cell.
This persistent drug resistance highlights the urgent need for strategies that can help ADCs escape the endosome and deliver their life-saving payload directly where it is needed most.
Breaking free from the endosome is therefore critical for maximizing the cancer-killing effect of ADCs and improving patient outcomes.
Our Solution
Defence Therapeutics has developed a proprietary bioconjugate called ACCUM, with the ability to disrupt endosomal membranes and allowing for large therapeutics to escape.
When Accum-conjugated ADCs enter a cancer cell, they escape from the endosome and bypass typical resistance mechanisms. Freed from the endosome, the ADC releases its toxic payload throughout the cell, targeting essential components needed for the cancer cell’s survival.
The outcome is a decisive, cell-killing response where previous therapies fell short.
Advantages
Novel Escape Mechanism
Enables More Therapies
Improves Proven Drugs
Leverages Natural Pathways
Recent Scientific Highlights
Completed studies have proven Accum to be
very stable, enabling higher drug retention
Recent in vivo trials have proven the ability of Accum to significantly improve results
Increased intracellular accumulation of delivered drugs by 10x compared to current ADCs